Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis

被引:42
作者
Frieri, M
Therattil, J
Chavarria, V
Cosachov, J
Kumar, NS
Wang, SF
Sansone, G
Etzel, J
Dellevecchia, D
Zitt, M
Mesarina-Wicki, B
Nolop, KB
机构
[1] Nassau Cty Med Ctr, Dept Med, Div Clin Immunopathol, E Meadow, NY 11554 USA
[2] Nassau Cty Med Ctr, Dept Pathol, Div Clin Immunopathol, E Meadow, NY 11554 USA
关键词
D O I
10.1016/S1081-1206(10)63141-9
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Mometasone furoate is a potent glucocorticoid that can markedly inhibit proinflammatory Th-2 cytokines in vitro. An aqueous nasal spray formulation has been shown to be clinically active in reducing the symptoms of perennial and seasonal allergic rhinitis. Objective: To determine whether pretreatment with mometasone furoate 200 E mu g once daily decreases specific indices of early and late phase nasal inflammation compared with placebo. Methods: A randomized, double-blind, placebo-controlled crossover study was conducted using nasal provocation with ragweed antigen in 21 patients with ragweed-induced allergic rhinitis out of the ragweed season; the treatment period was 2 weeks. Symptom scores, rhinoprobe cytology, and nasal lavage fluid were collected during early and late phase periods for nasal cytokines (interleukin, 1, 4, 5, 6, and 8) and leukotriene B-4 determinations using ELISA and RIA. Results: Mean nasal symptom scores and sneezing frequency were consistently lower with mometasone furoate compared with placebo. Treatment was associated with a statistically significant early phase (30-minute time point) reduction in nasal lavage histamine levels compared with placebo (14.3 versus 20.2 ng/mL, P = .02). Within-treatment comparisons suggested that mometasone furoate reduced the antigen-induced late-phase response for IL-6, IL-8, and eosinophils compared with pretreatment. There were similar, but smaller, changes seen in the placebo group for these measurements. There were no statistically significant changes following antigen challenge in IL-1, IL-4, IL-5, LTB4, or in other nasal cytology parameters. Conclusion: These results suggest that the clinical activity of mometasone furoate nasal spray in seasonal allergic rhinitis is likely due, in part, to a reduction in the levels of histamine in nasal secretions related to the early phase response, and reductions in IL-6, IL-8, and eosinophils during the late phase response.
引用
收藏
页码:431 / 437
页数:7
相关论文
共 30 条
[1]   DEVELOPMENT OF A NEW TECHNIQUE FOR RECOVERY OF CYTOKINES FROM INFLAMMATORY SITES INSITU [J].
ALAM, R ;
SIM, TC ;
HILSMEIER, K ;
GRANT, JA .
JOURNAL OF IMMUNOLOGICAL METHODS, 1992, 155 (01) :25-29
[2]  
BACHERT C, 1992, Journal of Allergy and Clinical Immunology, V89, P179
[3]  
BRADDING P, 1993, J ALLERGY CLIN IMMUN, V91, P180
[4]   NASAL CHALLENGE WITH RAGWEED POLLEN IN HAY-FEVER PATIENTS - EFFECT OF IMMUNOTHERAPY [J].
CRETICOS, PS ;
ADKINSON, NF ;
KAGEYSOBOTKA, A ;
PROUD, D ;
MEIER, HL ;
NACLERIO, RM ;
LICHTENSTEIN, LM ;
NORMAN, PS .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (06) :2247-2253
[5]   Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients [J].
Drouin, M ;
Yang, WH ;
Bertrand, B ;
VanCauwenberge, P ;
Clement, P ;
Dalby, K ;
Darnell, R ;
Ernst, TM ;
Hebert, J ;
Karlsson, G ;
Luciuk, G ;
Mazza, J ;
Roovers, M ;
Ruoppi, P ;
Seppey, M ;
Stern, M ;
Suonpaa, J ;
Sussman, G ;
Tan, KY ;
Tse, K ;
Widjaja, P ;
Jensen, P ;
Nolop, K ;
Lutsky, BN .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1996, 77 (02) :153-160
[6]  
DURHAM SR, 1992, J IMMUNOL, V148, P2390
[7]  
Fried M., 1993, ASTHMA MANAGEMENT, V2, P25
[8]  
FRIEDMAN E, 1995, CRIT REV, V9, P1
[9]  
FRIERI M, 1993, ANN ALLERGY, V70, P13
[10]  
FRIERI M, 1993, J ALLERGY CLIN IMMUN, V91, P182